|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����ԭ |
|
���ɫ�������������A |
|
���Ժ����� |
|
�����Ʒ� |
| ��������������� | |
|
��º� |
|
½��� |
|
�̲� |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
|
Article by |
����ԭ���ƶ��Ժ�������ʵ���о���չ
��º�, ½���, �̲�, ����
����ҽѧԺ����ҽԺƤ���� 550004
����ԭ��������ͨ��ԭ��ͬ����ʽ��������T�ܰ�ϸ��,��������Ŀ��������߹��ܡ�������һ����,������ԭ����Ӧ�Ŀ�������ؿ�ԭ�ĵ����Ƴ��ںϵ���,�Դ����ƶ��Ժ�����,������Ա����Ӧ��������ؿ�ԭ��B16������ϸ������ǿ�ҵ�ɱ������,����С��Ĵ���ڿɵõ��ӳ���ͨ���յ�SEA��������Ҫ��֯�����Կ�ԭ������ӽ��λ���ͻ��������ϸ������,���ɽ��������ںϵ������µĶ�������,����ǿ�俹����ЧӦ������,������ԭ����תȾ���ƶ��Ժ�������ʵ�鶯������Ҳȡ���˽Ϻõ���Ч��
[2] Tordsson JM,Ohlsson LG,Abrahmsen LB,et al.Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.Cancer Immunol Immunother,2000,48(12):691-702.
[3] Krull F,Holzer U,Ihle J,et al.Superantigen-induced lysis of melanoma cells.Melanoma Res,1997,7(3):214-222.
[4] Dohlsten M,Abrahmsen L,Bjork P,et al.Monoclonal antibody-superantigen fusion proteins:tumor-specific agents for T-cell-based tumor therapy.Proc Natl Acad Sci USA,1994,91(19):8945-8949.
[5] Litton MJ,Dohlsten M,Rosendahl A,et al.The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.BrJ Cancer,1999,81(2):359-366.
[6] Dohlsten M,Hansson J,Ohlsson L,et al.Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.Proc Natl Acad Sci USA,1995,92(21):9791-9795.
[7] Rosendahl A,Kristensson.K,Hansson J,et al.Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.Int J Cancer,1998,76(2):274-283.
[8] Rosendahl A,Kristensson K,Hansson J,et al.Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.Int J Cancer,1998,76(2):274-283.
[9] Labuda T,Wendt J,Hedlund G,et al.ICAM-1 costimulation induces IL2 but inhibits IL-10 production in superantigen-activated human CD4+ T cells.Immunology,1998,94(4):496-502.
[10] Rosendahl A,Kristensson K,Hansson J,et al.Perforin and IFN-gamra are involved in the antitumor effects of antibody-targeted superantigens.J Immunol,1998,160(11):5309-5313.
[11] Litton MJ,Dohlsten M,Hansson J,et al.Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.Am J Pathol,1997,150(5):1607-1618.
[12] Newton DW,Dohlsten M,Lando PA,et al.MHC class ��-independent,Vbeta-specific activation of T cells by superantigen mutants fused to antitumor Fab fragments:implications for use in treatment of human colon carcinoma.Int J Mol Med,1998,1(1):157-162.
[13] Hansson J,Ohlsson L,Persson R,et al.Genetically engineered superantigens as tolerable antitumor agents.Proc Natl Acad Sci U S A,1997,94(6):2489-2494.
[14] Rosendahl A,Hansson J,Antonsson P,et al.A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo.Infect Immun,1997,65(12):5118-5124.
[15] Sogaard M,Ohlsson L,Kristensson K,et al.Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation,and long-term survival of mice with established tumors.Int J Oncol,1999,15(5):873-882.
[16] Rosendahl A,Kristensson K,Carlsson M,et al.Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumortargeted IL-2 and SEA.Int J Cancer,1999,81(1):156-163.
[17] Wang Q,Yu H,Ju DW,et al.Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.Gene Ther,2001,8(7):542-550.
[18] Shrayer DP,Kouttab N,Hearing VJ,et al.Immunization of mice with melanoma cells transfected to secrete the superantigen,staphylococcal enterotoxin A.Cancer Immtnol Immunother,1998,46(1):7-13.
[19] Walsh P,Gonzalez R,Dow S,et al.A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma.University of Colorado Cancer Center Clinical Trial.Hum Gene Ther,2000,11(9):1355-1368.
[20] Dow SW,Elmslie RE,Willson AP,et al.In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.JClin Invest,1998,101(11):2406-2414.